Longevity: how to live to be 100. Here’s what science really says
The recipe is not a miraculous elixir of long life, but the sum of many small factors of resilience — genetic, metabolic and behavioural — which, taken together, achieve this feat
Key points
At a time when the sustainability of our welfare system is increasingly under threat, to the extent that it is forcing us to take unpopular measures such as raising the retirement age ever higher, thereby robbing the ‘silver economy’ generation of precious months of their well-deserved retirement, science seems to have realised the urgency of turning us all into a host of Methuselahs, preferably in good health. Meanwhile, however, Professor Gilles Allali of the CHUV (Leenaards Memory Centre at Lausanne University Hospital) assures us that our brains can continue to develop even in old age. Provided – of course – that we do not ‘retire’ it, but continue to stimulate it. And this is already a first practical piece of advice.
The most advanced anti-ageing studies
And 2026 will be remembered as the year that marked a major turning point in longevity research with the launch of the first-in-human trials on epigenetic cell reprogramming. One such example is the treatment of a patient suffering from glaucoma using so-called Yamanaka factors (the Japanese scientist is on the cover of the August issue of TIME) to rejuvenate the damaged cells in the eye.
Just recently, a consortium led by Mount Sinai in New York published the most detailed genetic map of the brain ever produced in journals belonging to the Nature group: 6.3 million cells from nearly 1,500 donors, both healthy and unwell. The most surprising finding is that the brain ages in spurts, rather than gradually. Three key turning points have been identified: following rapid remodelling in early childhood, there is a period of long-term stability from the age of 24 onwards, whilst after the age of 60 there is a veritable tsunami of molecular changes. It is at this point that the brain’s immune cells cease to follow the circadian clock and begin to operate at a pace dictated by stress and inflammation. By cross-referencing the data, the researchers discovered that Alzheimer’s, Parkinson’s and schizophrenia share certain common molecular mechanisms, whilst retaining specific cellular ‘signatures’; a valuable clue for developing more targeted therapies against diseases hitherto considered distinct from one another.
A few months ago, another major study published in *b* *Cell* , which analysed 500 samples of human tissue, had established that the watershed – the molecular marker of ageing, the ‘midpoint of our life’s journey’ – was the age of 50; from this age onwards, ageing kicks into high gear at the protein level (the ‘building blocks’ of the body) and the first to show signs of ageing are the blood vessels.
And a major anti-ageing competition is also helping to attract top talent. It’s called the XPRIZE Healthspan and is a sort of global contest between the brightest minds in the science of longevity. Over the past few years, a judging panel comprising more than a dozen experts has selected the most promising scientific proposals on how to extend life whilst improving its quality. In July, the shortlist of finalists was narrowed down to 10 teams, each of which received one million dollars to begin advanced testing of their project over the next four years. The winning team will not be announced until 2030.

